medmix AG (MEDX) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of medmix AG CHF 3.30, price CHF 9.94, upside -66.8%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch medmix AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range CHF 7.79 – CHF 42.05 · fair‑value band CHF 2.98 – CHF 4.13 · the CHF 9.94 price screens above the CHF 3.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow medmix in your weekly email
Every Wednesday you see whether medmix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments.
Show more
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of diabetes, osteoporosis, and other diseases; and the delivery and mixing devices, which are used by tissue banks and medical device OEMs. It also produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in construction, transportation, electronics, infrastructure, and general industrial sectors; and micro-brushes and applicators for eyes, eyelashes, lips, and facial make-up. The company offers its products under the Mixpac, Transcodent, Qiaoyi, Cox, MK, Medmix, Haselmeier, and Geka brands. medmix AG was founded in 1922 and is based in Baar, Switzerland.
Stock analysis
medmix AG (MEDX) currently trades at CHF 9.94, while our model-based Fair Value estimate is CHF 3.30, implying the stock looks roughly 201.2% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of CHF 7.01 per share, and 3 of the 24 models we run sit above the CHF 9.94 price.
Bear case: the Earnings-Based group reads lowest at CHF 1.35, and 21 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: CHF 2.98 (bear) to CHF 4.13 (bull), the price of CHF 9.94 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Industrials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
medmix AG reported revenue of CHF 448M in FY2025 versus CHF 457M in FY2021, a compound −0.5%/yr. Reported net income was CHF 6.4M in FY2025, compounding −38.2%/yr from FY2021.
Key figures
Market cap CHF 413M · P/E ratio 66.3 · P/S ratio 0.95 · EPS (TTM) CHF 0.1500 · Dividend yield 1.0% · Net margin 1.4% · Return on equity 1.6% · Return on assets (EBIT) 2.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −49% fair-value upside, at −67%, MEDX screens richer than that median.
Fair Value models
Bear CHF 2.98Fair Value CHF 3.30Bull CHF 4.13
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (CHF 0.0371 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−7.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−23.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−24.1%
Dividend (yield on the price)1.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 6%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +7.5% a year for the price and +3.4% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Industrial Machinery · 813 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−66.8% · Bottom 25%
Profitability
Return on equity (TTM)1.6% · Below median
Return on assets1.9% · Below median
Net margin (TTM)1.4% · Below median
Operating margin (TTM)5.5% · Below median
Growth and dividend
Revenue growth−8.3% · Bottom 25%
Dividend yield (TTM)1.0% · Below median
Balance sheet
Debt / equity0.59× · Highest 25%
Valuation Multiplesvs Specialty Industrial Machinery median · lower = cheaper
P/E (TTM)66.3× · Priciest 25%
P/B0.97× · Cheapest 25%
P/S (TTM)0.92× · Cheaper than median
P/FCF12.4× · Cheaper than median
EV/EBITDA7.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 23
PAST (return on equity)6· sector 28
HEALTH (low debt)71· sector 96
DIVIDEND (yield)20· sector 25
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "medmix AG Fair Value". https://www.fairvalue-calculator.com/stock/MEDX
Frequently asked questions
Is medmix AG (MEDX) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of CHF 3.30 versus a price of CHF 9.94, about −67% upside (overvalued).
What is the fair value of MEDX?
Our model-based fair value for medmix AG is CHF 3.30 (as of Sep 27, 2026), built from audited fundamentals. The current price: CHF 9.94.
What is the quality score of MEDX?
medmix AG has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for medmix AG (MEDX)?
Our model-based price target is the fair value of CHF 3.30 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario CHF 2.98, optimistic scenario CHF 4.13. It is a calculation from audited fundamentals, not an analyst target.
What is the medmix AG stock forecast for 2026?
Our models put fair value at CHF 3.30, about −67% upside versus a price of CHF 9.94 (overvalued). Cautious scenario CHF 2.98, optimistic scenario CHF 4.13. The calculation is refreshed regularly with new filings.
What is the revenue of medmix AG (MEDX)?
medmix AG reported trailing-twelve-month revenue of about CHF 448M (latest available figure, as of Sep 27, 2026).
Does medmix AG pay a dividend?
medmix AG currently shows a dividend yield of about 1.01% relative to its recent price (as of Sep 27, 2026).
What growth is priced into medmix AG (MEDX)?
For today's price to be fair in a discounted-cash-flow model, medmix AG would have to grow free cash flow by +8.1 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.0 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of MEDX use?
Our models discount medmix AG at 10.5 %: a base by market capitalisation (small), damped by beta 0.81, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For medmix AG that is +8.1 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has medmix AG (MEDX) delivered so far?
Over the past 5 years revenue at medmix AG grew +5.0 % a year. The price currently implies +8.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of medmix AG (MEDX) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into medmix AG (+8.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of medmix AG (MEDX)?
The free-cash-flow yield on the price is 8.07 %: that much free cash flow medmix AG produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of medmix AG (MEDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For medmix AG it is CHF 3.30 per share (as of Sep 27, 2026), against a price of CHF 9.94. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is medmix AG stock overvalued or undervalued in 2026?
As of Sep 27, 2026, MEDX trades above its calculated fair value: price CHF 9.94, fair value CHF 3.30, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDX?
No. The price is what the market pays today (CHF 9.94); the fair value is what the company's own numbers justify (CHF 3.30). For medmix AG the two are CHF 6.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is medmix AG worth?
The market values medmix AG at about CHF 413M (market capitalisation, as of Sep 27, 2026). Per share that is CHF 9.94; our models calculate a fair value of CHF 3.30 per share.
What do the bullish and bearish scenarios say about MEDX?
Our models span a range for medmix AG: cautious scenario CHF 2.98, base CHF 3.30, optimistic CHF 4.13 per share (as of Sep 27, 2026, price CHF 9.94). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDX?
medmix AG trades at a price-to-earnings ratio of 66.3 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 3.30 is built from several models across several years. Other multiples: P/B 1.0, P/S 0.9, EV/EBITDA 7.6.
How solid is the balance sheet of medmix AG (MEDX)?
Balance-sheet figures for medmix AG (as of Sep 27, 2026): return on equity 1.6%, debt of 0.59 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is MEDX from its 52-week high?
medmix AG trades at CHF 9.94, about 17% below its 52-week high of CHF 11.95 and 26% above the low of CHF 7.87 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 3.30 is for.
Which stocks are comparable to medmix AG?
From the same area (Industrials) we also value GE Vernova Inc, SIE, Eaton Corporation, Parker-Hannifin Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is medmix AG stock attractive at the current price?
The data as of Sep 27, 2026: price CHF 9.94, calculated fair value CHF 3.30 (−67%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDX calculated?
We run medmix AG through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 3.30, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. medmix AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of medmix AG (MEDX)?
The closing price on Sep 28, 2026 was CHF 9.94. Our model-based fair value is CHF 3.30, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with medmix AG right now?
The price sits above even our optimistic bull case (CHF 4.13). The favourable scenario is already priced in. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of medmix AG
How large is the market capitalisation of medmix AG (MEDX)?
The market capitalisation of medmix AG is CHF 413M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of medmix AG (MEDX)?
The price-to-sales ratio of medmix AG is 0.95 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of medmix AG (MEDX)?
Earnings per share at medmix AG are CHF 0.1500 (price ÷ EPS = P/E 66.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of medmix AG (MEDX)?
The dividend yield of medmix AG is 1.0% (payout 66.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of medmix AG (MEDX)?
The net margin of medmix AG is 1.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of medmix AG (MEDX)?
The return on equity (ROE) of medmix AG is 1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of medmix AG (MEDX)?
On an EBIT basis the return on assets of medmix AG is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of medmix AG (MEDX)?
The operating margin of medmix AG is 5.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at medmix AG (MEDX)?
Revenue at medmix AG is growing −8.3% versus a year earlier (3y avg −2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at medmix AG (MEDX)?
Earnings per share at medmix AG are growing +33.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does medmix AG (MEDX) carry?
The net debt of medmix AG is CHF 286M (fiscal year 2025, ≈ 8.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch medmix AG in the live analysis
One click puts medmix AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
